Pharmacological Ascorbate Formulations Combined with EDTA Enhance Tumor Cell Killing
- 詳細技術說明
- This is a new methodof improving the treatment of NSCLC and other cancers. It involvesadministering a novel combination of ascorbate and a metal chelating agent,such as ethylene diamine tetraacetic acid (EDTA), to increase tumor cellssensitivity to common cancer treatment options. When this combination isadministered to a patient, tumor cells have a much lower survival rate than whensubjected to traditional chemotherapy and radiation therapy methods. Increasing the efficacy of these methods couldlower the total cost and treatment time as well as improve patient outcome. Thistechnology could also reduce the need for risky surgical procedures by makingless invasive treatment options, like chemotherapy, more effective.
- *Abstract
-
Advantages
- Increases the efficacy of existing chemotherapy and radiation therapies
- Low FDA hurdles (ascorbate and EDTA are commercially available compounds)
- Could reduce the cost of cancer treatment
BackgroundInformation
Ascorbate (vitaminC) in combination with anti-cancer metal chelating agents has been shown to beeffective in the treatment of many different types of cancer, including non-smallcell lung cancer (NSCLC). Currently, the main methods of treating NSCLC arechemotherapy, radiation therapy, and/or surgically removing the malignant cells.Lung cancer patients have the lowest survival rates – as low as 49% for stage Ipatients, and 1% in stage IV patients. It has been found that increased levelsof ascorbate in the body is toxic to tumor cells. When ascorbate isadministered with a metal chelating agent, the combination increases oxidativestress in tumors, and thus, its efficacy in killing cancer cells increases whencombined with radiation and/or chemotherapy.
TechnologySummary
This is a new methodof improving the treatment of NSCLC and other cancers. It involvesadministering a novel combination of ascorbate and a metal chelating agent,such as ethylene diamine tetraacetic acid (EDTA), to increase tumor cellssensitivity to common cancer treatment options. When this combination isadministered to a patient, tumor cells have a much lower survival rate than whensubjected to traditional chemotherapy and radiation therapy methods. Increasing the efficacy of these methods couldlower the total cost and treatment time as well as improve patient outcome. Thistechnology could also reduce the need for risky surgical procedures by makingless invasive treatment options, like chemotherapy, more effective.
- *Licensing
- Email: uirf-marketing@uiowa.eduPhone: (319) 335-4546
- 國家/地區
- 美國
